Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Hydrocortisone sodium phosphate [USAN:USP:BAN:JAN]
RN: 6000-74-4
UNII: 0388G963HY
InChIKey: RYJIRNNXCHOUTQ-OJJGEMKLSA-L

Note

  • The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.

Molecular Formula

  • C21-H31-O8-P.2Na

Molecular Weight

  • 486.4061
 

Classification Codes

  • Drug / Therapeutic Agent
  • Glucocorticoid
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Hydrocortisone sodium phosphate
  • Hydrocortisone sodium phosphate [USAN:USP:BAN:JAN]

Synonyms

  • Actocortin
  • Actocortina
  • Coriphate
  • Cortisol 21-(disodium phosphate)
  • Cortisol sodium phosphate
  • Efcortesol
  • EINECS 227-843-9
  • Hidroaltesona
  • Hydrocortisone 21-sodium phosphate
  • Hydrocortisone disodium phosphate
  • Hydrocortisone sodium phosphate
  • Hydrocortone
  • Hydrocortone Phosphate
  • Idracemi
  • Physiocortison
  • Sodium hydrocortisone 21-phosphate
  • UNII-0388G963HY

Systematic Names

  • Cortisol, 21-(dihydrogen phosphate), disodium salt
  • Pregn-4-ene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, disodium salt, (11beta)-

Registry Numbers

CAS Registry Number

  • 6000-74-4

FDA UNII

  • 0388G963HY

System Generated Number

  • 0006000744

Molecular Formulas

Molecular Formula

  • C21-H31-O8-P.2Na

Molecular Formula Fragments

  • C21-H31-O8-P
  • COMPONENT
  • Na

Structure Descriptors

InChI

1S/C21H31O8P.2Na/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19;;/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28);;/q;2*+1/p-2/t14-,15-,16-,18+,19-,20-,21-;;/m0../s1

InChIKey

RYJIRNNXCHOUTQ-OJJGEMKLSA-L

Smiles

[C@@]12([C@H]([C@H]3[C@H]([C@H](C2)O)[C@@]2(C(=CC(=O)CC2)CC3)C)CC[C@@]1(C(=O)COP(=O)([O-])[O-])O)C.[Na+].[Na+]

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intramuscular 930mg/kg (930mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2117, 1979.
mouse LD50 intraperitoneal 740mg/kg (740mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2117, 1979.
mouse LD50 intravenous 746mg/kg (746mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 17, Pg. 849, 1975.
mouse LD50 oral 3950mg/kg (3950mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2117, 1979.
mouse LD50 subcutaneous 692mg/kg (692mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 17, Pg. 849, 1975.
rat LD50 intramuscular 1500mg/kg (1500mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2117, 1979.
rat LD50 intraperitoneal 603mg/kg (603mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Yakkyoku. Pharmacy. Vol. 26, Pg. 379, 1975.
rat LD50 intravenous 632mg/kg (632mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Yakkyoku. Pharmacy. Vol. 26, Pg. 379, 1975.
rat LD50 oral 6100mg/kg (6100mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2117, 1979.
rat LD50 subcutaneous 680mg/kg (680mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2117, 1979.